Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: Role of TGF-β1

Carcinogenesis

Volumn 23, Issue 10, 2002, Pages 1569-1576

  Tavassoli, Mahvash ^a   Soltaninia, Jila ^a   Rudnicka, Joanna ^a   Mashanyare, Dorothy ^a   Johnson, Newell ^a   Gäken, Joop ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE C; PROTEIN P15; PROTEIN P21; PROTEIN P27; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELLS, CULTURED; CISPLATIN; DNA, NEOPLASM; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; TAMOXIFEN; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036798785     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Clayman, G.L., Ebihara, S., Terada, M., Mukai, K. and Goepfert, H. (1997) Report of the Tenth International Symposium of the Foundation for Promotion of Cancer Research: Basic and clinical research in head and neck cancer. Jap. J. Clin. Oncol., 27, 361-368.
2. Forastiere, A.A., Metch, B., Schuller, D.E., et al. (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck - A Southwest-Oncology-Group study. J. Clin. Oncol., 10, 1245-1251.
3. Brennan, J.A., Boyle, J.O., Koch, W.M., Goodman, S.N., Hruban, R.H., Eby, Y.J., Couch, M.J., Forastiere, A.A. and Sidransky, D. (1995) Association between cigarette-smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New Engl. J. Med., 332, 712-717.
4. Clayman, G.L., Elnaggar A.K., Roth, J.A., Zhang, W.W., Goepfert, H., Taylor, D.L. and Liu, T.J. (1995) In-vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res., 55, 1-6.
5. Cohen, S.M. and Lippard, S.J. (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol., 67, 93-130.
6. Lara, P.N. Jr, Gandara, D.R., Longmate, J., et al. (2001) Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother. Pharmacol., 48, 22-28.
7. Tanaka, T., Masuda, H., Naito, M. and Tamai, H. (2001) Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Anti Cancer Res., 21, 2463-2469.
8. McClay, E.F., McClay, M.T., Monroe, L., Jones, J.A. and Winski, P.J. (2001) A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.. Melanoma Res., 11, 309-313.
9. Tan, C.K, Chow, P.K., Findlay, M., Wong, C. and Machin, D. (2000) Use of tarnoxifen in hepatocellular carcinoma: a review and paradigm shift. J. Gastroenterol. Hepatol., 15, 725-729.
10. Mandlekar, S., Yu, R., Tan, T.H. and Kong, A.N. (2000) Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res., 60, 5995-6000.
11. Pollack, I.F., DaRosso, R.C., Robertson, P.L., et al. (1997). A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res., 3, 1109-1115.
12. O'Brian, C.A., Liskamp, R.M., Solomon, D.H. and Weinstein, I.B. (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res., 45, 2462-2465.
13. Mandlekar, S. and Kong, A.N. (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 6, 469-477.
14. Colletta, A.A., Wakefield, L.M, Howell, F.V, van Roozendaal, K.E., Danielpour, D., Ebbs, S.R., Sporn, M.B. and Baum, M. (1990) Antioestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer, 62, 405-409.
15. Butta, A., MacLennan, K., Flanders, K.C., et al. (1992). Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264.
16. Derynck, R., Akhurst, R.J. and Balmain, A. (2001) TGF-beta signalling in tumour suppression and cancer progression. Nat Genet., 29, 117-129.
17. Zhang, H.S., Postigo, A.A. and Dean, D.C. (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16 (INK4a), TGF beta and contact inhibition. Cell, 97, 53-61.
18. Hannon, G.I. and Beach, D. (1994) p15 (INK4b) is a potential effector of TGF-beta-induced cell-cycle arrest. Nature, 371, 257-261.
19. Hartwell, I.H. and Kastan, M.B. (1994) Cell-cycle control and cancer. Science, 266, 1821-1828.
20. Akagi, M., Yasui, W., Akama, Y., Yokozaki, H., Tahara, H., Haruma, K., Kajiyama, G. and Tahara, E. Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p2l in gastric carcinoma cells. Jap. J. Cancer Res., 87, 377-384.
21. Robson, C.N., Gnanapragasam, V., Byrne, R.L, Collins, A.T. and Neal, D.E. (1999) Transforming growth factor-beta 1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol., 160, 257-266.
22. Herrera, R.E., Makela, T.P. and Weinberg, R.A. (1996) TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol. Biol. of Cell, 7, 1335-1342.
23. Gerwin, B.I., Spillare, E., Forrester, K., et al. (1992) Mutam-p53 can induce tumorigenic conversion of human bronchial epithelial-cells and reduce their responsiveness to a negative growth-factor, transforming growth factor-beta (1). Proc. Natl Acad. Sci. USA, 89, 2759-2763.
24. Rusthoven, J.J. (1998) The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Eur. J. Cancer, 34, S31-36.
25. McClay., E.F., McClay M.E., Monroe, L., Baron, P.L, Cole, D.J., O'Brien, P.H., Metcalf, J.S. and Maize, J.C. (2000) The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br. J. Cancer, 83, 16-21.
26. Lin, C.C., Hsu, C.H., Chen, J., Tsai, T.C, Cheng, A.L. and Pu, Y.S. (2001) A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res., 21 (2B), 1385-1390.
27. Hsu, C.., Chen, J., Wu, C.Y., Cheng, A.L. and Pu, Y.S. (2001) Combination chemotherapy of cisplatin, methotrexate, vinblastine and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res., 1 (1B), 711-715.
28. Chen, Y., Perng, R.P., Yang, K.Y., Lin, W.C., Wu, H.W., Tsai, C.M. and Whang-Peng, J. (2000) Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer, 29, 139-146.
29. Sartor, M., Steingrimsdottir, H., Elamin, F., Gaken, J., Warnakulasuriya, S.M., Thakke, N., Johnson, N.W. and Tavassoli, M. (1999) Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br. J. Cancer, 80, 79-86.
30. Blackwell, K.L., Haroon, Z.A., Shan, S., Saito, W., Broadwater, G., Greenberg, C.S. and Dewhirst, M.W. (2000) Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin. Cancer Res., 6, 4359-4364.